HC Wainwright reaffirmed their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $6.00 price objective on the stock. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q2 2024 earnings at ($1.02) EPS, Q3 2024 earnings at ($1.09) EPS, […]